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X-linkedmuscular dystrophy is a highly progressive disease of childhood and characterized by primary genetic abnormalities in the
dystrophin gene. Senescent mdx specimens were used for a large-scale survey of potential age-related alterations in the dystrophic
phenotype, because the established mdx animal model of dystrophinopathy exhibits progressive deterioration of muscle tissue
with age. Since the mdx tibialis anterior muscle is a frequently used model system in muscular dystrophy research, we employed
this particular muscle to determine global changes in the dystrophic skeletal muscle proteome. The comparison of mdx mice
aged 8 weeks versus 22 months by mass-spectrometry-based proteomics revealed altered expression levels in 8 distinct protein
species. Increased levels were shown for carbonic anhydrase, aldolase, and electron transferring flavoprotein, while the expressions
of pyruvate kinase, myosin, tropomyosin, and the small heat shock protein Hsp27 were found to be reduced in aged muscle.
Immunoblotting confirmed age-dependent changes in the density of key muscle proteins in mdx muscle. Thus, segmental necrosis
in mdx tibialis anterior muscle appears to trigger age-related protein perturbations due to dystrophin deficiency. The identification
of novel indicators of progressive muscular dystrophymight be useful for the establishment of a muscle subtype-specific biomarker
signature of dystrophinopathy.
1. Introduction
Voluntarymuscle fibres are one of themost abundant cellular
units in the body. Skeletal muscle tissues are responsible
for the provision of postural control, the coordination of
excitation-contraction-relaxation cycles for voluntary move-
ments, the integration of key metabolic and biochemical
pathways, and the regulation of heat homeostasis. Under
normal physiological conditions, these highly complex cel-
lular tasks require a large and diverse number of protein
interactions. Hence, supramolecular protein complexes with
specialized functions, structures, and connections represent
a major biochemical feature of muscle fibres. An excellent
example of a large protein assembly present in skeletal muscle
is the dystrophin-glycoprotein complex of the sarcolemma
[1–5]. The crucial importance of the dystrophin-associated
protein complex is exemplified by the pathophysiological
fact that primary genetic abnormalities in the dystrophin
gene result in progressive muscle wasting diseases, such
as Duchenne or Becker muscular dystrophy [6–8]. In
normal muscle, the dystrophin-glycoprotein complex pro-
vides a trans-sarcolemmal linkage between the actin mem-
brane cytoskeleton and the extracellular matrix component
laminin [2]. The subsarcolemmal dystrophin matrix and the
molecular connection between the basal lamina structure
and the muscle interior is believed to prevent damage to the
muscle surface from potential membrane-distorting forces
during contraction-relaxation cycles [5].
In X-linked muscular dystrophy, dystrophin deficiency
results in a drastic reduction of sarcolemmal glycoproteins
that triggers a loss of plasmalemmal integrity [9]. Dys-
trophic muscle fibres are more susceptible to contraction-
induced injury [10] and their lateral transmission of force
is impaired [11]. Cycles of sarcolemmal microrupturing
and natural membrane repair mechanisms appear to cause
the introduction of Ca2+-leak channels [12] that in turn
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elevate cytosolic Ca2+-levels [13] and disturb Ca2+-fluxes
through the sarcoplasmic reticulum in dystrophic fibres
[14–16]. Interestingly, a recent study on the therapeutic
effect of upregulating the intramuscular heat shock protein
Hsp72 to ameliorate the dystrophic phenotype revealed that
the SERCA-type Ca2+-ATPase is dysfunctional in severely
dystrophic muscle [17]. These findings strongly indicate
that impaired Ca2+-homeostasis plays a key role in X-linked
muscular dystrophy. However, it is not well understood
how many molecular and cellular factors are involved in
the overall process leading to the highly complex pathology
of dystrophinopathy. Thus, in order to determine the
hierarchy of secondary pathobiochemical effects that render
a dystrophic muscle more susceptible to necrosis, it is crucial
to elucidate global alterations due to the disintegration of the
dystrophin-glycoprotein complex [18]. Mass-spectrometry-
based proteomics suggests itself as a suitable analytical tool
for such large-scale and high-throughput approaches to
study the effects of dystrophin deficiency.
In contrast to hypothesis-based and targeted bioresearch,
proteomics can be considered an unbiased and technology-
driven approach for the comprehensive cataloging of entire
protein complements [19–21]. Skeletal muscle proteomics
in particular is concerned with the global identification and
detailed cataloguing of the protein constituents of voluntary
contractile fibres in health and disease [22–24]. In the long
term, comparative proteomics promises to be instrumental
for the establishment of comprehensive biomarker signatures
of myogenesis, muscle repair mechanisms, physiological
adaptations and pathological changes [25], as well as the
natural aging process [26]. Most gel electrophoresis-based
proteomic studies use high-resolution two-dimensional gel
electrophoresis in combination with advanced mass spectro-
metric analysis for the unequivocal identification of muscle
proteins of interest [27–29]. In the case of X-linked muscular
dystrophy, a variety of mass spectrometric investigations
have attempted to determine proteome-wide changes in
dystrophin-deficient muscle tissue in order to establish a
dystrophy-specific biomarker signature [30, 31].
Large-scale proteomic profiling studies have included
investigations of serum [32, 33], cardiac muscle [34, 35],
and various skeletal muscle tissues [16, 36–43] from the mdx
mouse model of Duchenne muscular dystrophy, as well as a
proteomic analysis of dystrophic GRMD dog skeletal muscle
[44]. Although the findings from individual studies do not
agree on the exact number and extent of protein alterations
within the dystrophic muscle proteome, all investigations
concur that dystrophin-deficient fibres exhibit a generally
perturbed protein expression pattern [30]. Previous gel
electrophoresis-based proteomic profiling studies of dys-
trophic samples have focused on the cytosolic fraction from
1, 3, and 6 months old hind limb muscle covering a pI range
of 4–7 and using Coomassie and silver-staining methods
[36, 37], crude extracts from gastrocnemius muscle from
9 weeks old hind limb tissue covering a pI range of 3–
10 and using Stains-All labeling [16], preparations from 6
weeks old gastrocnemius muscle covering a pI range of 3–
10 and using fluorescence 2D-DIGE labeling [38], crude
extracts from 9 weeks old diaphragm tissue covering a pI
range of 3–10 and using hot Coomassie staining [39], crude
extracts from 9 weeks old diaphragm muscle covering a pI
range of 3–10 and using fluorescence 2D-DIGE labeling [40],
crude extracts from 10 weeks old antisense oligomer-treated
diaphragm tissue covering a pI range of 3–10 and using
2D-DIGE labeling [41], crude extracts from 9 weeks old
extraocular muscle covering a pI range of 3–10 and using
fluorescence 2D-DIGE labeling [42], and crude extracts from
aged diaphragm muscle covering a pI range of 3–10 and
using fluorescence RuBPs labeling [43].
In analogy to the above-outlined proteomic studies, this
report has focused on aged tibialis anterior muscle from
dystrophic mdx mice. The tibialis anterior is one of the
most active lower leg muscles [45], which exhibits a relatively
high degree of resistance to fatigue during periods of intense
running [46], making it an interesting contractile system to
study with respect to secondary effects of dystrophinopathy.
In addition, previous experimental gene therapy studies have
focused on mdx tibialis anterior muscle [47]. Labeling of
proteins with fluorescent dyes has been extensively applied
in proteomic investigations [48] and we have used here
fluorescent RuBPs staining [49] for a comparative proteomic
survey of dystrophic leg muscle from 8 weeks, 12 months,
and 22 months old mdx mice. The densitometric analysis
of two-dimensional gels, covering a pI range of 3–10,
in combination with mass spectrometry identified signif-
icant age-related changes in carbonic anhydrase, aldolase,
electron transferring flavoprotein, pyruvate kinase, myosin,
tropomyosin, and the small heat shock protein Hsp27 in
dystrophic mdx tibialis anterior muscle.
2. Materials and Methods
2.1. Materials. Materials and electrophoresis-grade chem-
icals for the proteomic analysis of muscle proteins were
purchased from Amersham Biosciences/GE Healthcare, Lit-
tle Chalfont, Buckinghamshire, UK. For protein diges-
tion, sequencing grade-modified trypsin was obtained from
Promega (Madison, WI, USA). Chemiluminescence sub-
strate and protease inhibitors were from Roche Diagnostics
(Mannheim, Germany). Primary antibodies were obtained
from Vision Biosystems Novocastra, Newcastle upon Tyne,
UK (mAbNCL-b-DG to the dystrophin-associated glycopro-
tein β-dystroglycan) and Abcam, Cambridge, UK (ab54913
to the CA3 isoform of carbonic anhydrase; and ab12351 to
the small heat shock protein Hsp27). Secondary antibodies
were purchased from Chemicon International (Temecula,
CA). All other chemicals used were of analytical grade and
purchased from Sigma Chemical Company, Dorset, UK.
2.2. Dystrophic mdx Animal Model. The mdx mouse is an
established model system of X-linked muscular dystrophy
and widely used in basic research and for the evaluation
of novel therapeutic options to treat diseases of progressive
skeletal muscle wasting [50]. The mdx mouse is a naturally
occurring mutant [51] that is missing the Dp427 protein
isoform of the membrane cytoskeletal protein dystrophin
due to a point mutation in the dmd gene [52]. In analogy to
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the etiology of patients suffering from Duchenne muscular
dystrophy [9], deficiency in full-length dystrophin results in
a drastic reduction of all dystrophin-associated glycoproteins
in mdx skeletal muscle [53], making it a suitable animal
model for studying secondary pathobiochemical changes due
to dystrophin deficiency. Dystrophic tibialis anterior muscle
from 8 weeks, 12 months, and 22 months old mdx mice and
normal tissues from age-matched C57 mice were obtained
from the bioresource unit of the University of Bonn [54].
Mice were kept under standard conditions and all procedures
were performed in accordance with German guidelines on
the use of animals for scientific experiments. Animals were
sacrificed by cervical dislocation and muscle tissues quickly
removed and quick-frozen in liquid nitrogen.
2.3. Preparation of Skeletal Muscle Extracts from Aged mdx
Mice. For the mass spectrometry-based proteomic survey of
aged mdx skeletal muscle tissue, tibialis anterior specimens
were shipped to Ireland on dry ice and stored at −80◦C
prior to usage. In order to obtain muscle protein extracts,
4 dystrophic muscle specimens from each age group were
pulverized by grinding tissue pieces in liquid nitrogen using
a mortar and pestle. Ground muscle powder was solubilized
in lysis buffer with the ratio of 100mg wet weight to 1mL
lysis buffer (7M urea, 2M thiourea, 4% CHAPS, 2% IPG
buffer pH 3–10, 2% (w/v) DTT). To prevent excess protein
degradation, the lysis buffer was supplemented with a freshly
prepared protease inhibitor cocktail [35]. Following gentle
rocking for 30 minutes, suspensions were centrifuged at
4◦C for 20min at 20,000×g and the protein concentration
determined [55].
2.4. Two-Dimensional Fluorescence Gel Electrophoretic Anal-
ysis. For the separation of muscle proteins, standard two-
dimensional gel electrophoresis was carried out by previously
optimized methodology using first dimension isoelectric
focusing with pH 3–10 strips, and second dimension slab
gel electrophoresis with 500 μg protein per gel [55]. Twelve
slab gels were run in parallel at 0.5W/gel for 60min and
then 15W/gel until the blue dye front had disappeared from
the bottom of the gel. Postelectrophoretic staining for the
total protein profile was performed with the fluorescent dye
ruthenium II tris bathophenanthroline disulfonate (RuBPs).
As described previously by Rabilloud and colleagues [56], a
stock solution of RuBPs dye was prepared. Following washing
twice for 5min, gels were stained for 6 hours in 20% (v/v)
ethanol containing 200 nM of ruthenium chelate. Gels were
re-equilibrated twice for 10min in distilled water prior to
imaging [57]. Fluorescently labelled proteins from aged mdx
tibialis anterior muscle were visualised using a Typhoon
Trio variable mode imager. Gel analysis was performed
with Progenesis 2D analysis software and protein spots with
significantly altered expression levels were identified by mass
spectrometry.
2.5. Mass Spectrometric Identification of Proteins. Protein
identification was performed with 2D protein spots from
Coomassie-stained pick gels, following counter-staining of
RuBPs-labelled analytical gels. Excised protein spots were
treated by standardized in-gel tryptic digestion for the
generation of representative peptide mixtures. Excision,
washing, destaining, and treatment with sequencing-grade
trypsin were performed by a previously optimized method
[55]. Peptide populations were harvested by removing super-
natants from digested gel plugs after centrifugation. Further
recovery was achieved by adding 30% acetonitrile/0.2%
trifluoroacetic acid to the gel plugs for 10min at 37◦C with
gentle agitation. Resulting supernatants were pooled with
the initially recovered peptides following trypsin digestion.
Samples were dried through vacuum centrifugation and
concentrated peptide fractions were then suspended in mass
spectrometry-grade distilled water and 0.1% formic acid,
spun down through spin filters and added to LC-MS vials
for identification by ion trap LC-MS analysis. The mass
spectrometric analysis of peptides was carried out with
a Model 6340 Ion Trap LC/MS apparatus from Agilent
Technologies (Santa Clara, CA, USA). Separation of peptides
was performed with a nanoflow Aglient 1200 series system
equipped with a Zorbax 300SB C18 analytical reversed phase
column using HPLC-Chip technology. Mobile phases used
were A: 0.1% formic acid, B: 50% acetonitrile and 0.1%
formic acid. Samples were loaded into the enrichment part
of the chip at a capillary flow rate set to 4 μL/min with a
mix of solvent A and solvent B at a ratio of 19 : 1. Tryptic
digests were eluted with a linear gradient of 5% to 70%
solvent B over 6min, 70% to 100% solvent B over 1min,
100% to 5% over 1min. A 5min post-time of solvent A was
used to remove any potential carry over. The capillary voltage
was set to 2000V. The flow and temperature of the drying
gas were 4L/min and 300◦C, respectively. Database searches
were carried out with Mascot MS/MS ion search (Matrix
Science, London, UK; NCBI database, release 20100212).
All searches used “Mus musculus” as taxonomic category
and the following parameters: (1) two missed cleavages
by trypsin, (2) mass tolerance of precursor ions ±2.5Da
and product ions ±0.7Da, (3) carboxymethylated cysteins
fixed modification, (4) oxidation of methionine as variable
modifiaction, (5) percentage coverage was set at over 10%,
and (6) at least 2 matched distinct peptides. Mascot scores
over 50 are listed in Tables 1 and 2. All pI-values and
molecular masses of identified proteins were compared to
the relative position of their corresponding 2D spots on
analytical slab gels.
2.6. Immunoblot Analysis. One-dimensional immunoblot-
ting was employed to verify key findings from the pro-
teomic profiling of aged mdx tibialis anterior muscle. Gel
electrophoretic separation and transfer was carried out
with a Mini-Protean II electrophoresis and transfer system
from BioRad Laboratories (Hemel-Hempstead, Herts, UK).
Muscle proteins were transferred to nitrocellulose for 70
minutes at 100V and at 4◦C. Blocking of membranes was
achieved with a milk protein solution (5% (w/v) fat-free milk
powder in 0.9% (w/v) NaCl, 50mM sodium phosphate, pH
7.4) for 1 hour. Incubation with sufficiently diluted primary
antibody was carried out overnight with gentle agitation.
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Table 1: List of unchanged landmark 2D protein spots from normal mouse tibialis anterior muscle.
Spot
No.
Protein name Accession No.
Isoelectric
point (pI)
Molecular
mass (Da)
Number of
peptides
Coverage
Mascot score
(%)
1 Mitochondrial ATP synthase AAH37127 5.24 56,632 23 64 456
2 Unnamed protein [Mus musculus] BAC34145 5.75 70,730 12 21 230
3 Pyruvate kinase, isozymes M1/M2 NP 001240812 6.69 58,461 25 51 1149
4 Enolase, beta, isoform 1 NP 031959 6.73 47,337 21 56 450
5 Creatine Kinase, M-type NP 031736 6.58 43,250 23 47 509
6 Actin, beta CAA27396 5.78 39,446 12 41 103
7 Tropomyosin, beta chain NP 033442 4.66 32,931 22 59 395
8 Tropomyosin, beta chain NP 033442 4.66 32,933 32 15 241
9 Malate dehydrogenase, cytosolic AAA37423 6.16 36,625 9 36 190
10 Aldolase A, isoform 2 NP 031464 8.31 39,795 24 75 498
11 Glyceraldehyde-3-phosphate dehydrogenase NP 032110 8.44 36,072 14 57 238
12 Carbonic anhydrase CA3 NP 031632 6.89 29,638 12 43 431
13 Triosephosphate isomerase AAB48543 5.62 22,720 11 62 248
14 Triosephosphate isomerase AAB48543 5.62 22,720 11 68 638
15 Troponin TnI, fast skeletal muscle NP 033431 8.65 21,515 5 20 150
16 Adenylate kinase, isoenzyme 1 NP 067490 5.7 23,330 14 70 184
17 Myosin light chain MLC1/3 NP 067260 4.98 20,697 17 79 426
18 Myosin light chain MLC2 NP 058034 4.82 19,057 15 61 216
19 Myosin light chain MLC2 NP 058034 4.82 19,059 19 81 391
20 Myosin light chain MLC3 AAH59087 4.63 18,968 11 60 222
21 Parvalbumin, alpha NP 038673 5.02 11,923 12 89 622
22 Myoglobin NP 038621 7.07 17,116 5 37 98
Table 2: List of identified proteins that exhibit a drastic change in abundance during aging of the dystrophic mdx tibialis anterior muscle.
Spot
No.
Protein name Accession No.
Isoelectric
point (pI)
Molecular
mass (Da)
Number of
peptides
Coverage Mascot Fold change
8w-22m(%) Score
1 Carbonic anhydrase CA3 NP031632 6.89 29,638 4 26 181 2.9
2 Aldolase A isoform 2 NP031464 8.31 39,795 2 14 85 2.3
3
Electron transferring flavoprote-
in, beta
EDL22660 8.50 29,177 13 42 190 1.9
4 Carbonic anhydrase CA3 NP031632 6.89 29,638 12 53 182 1.7
5 Pyruvate kinase NP035229 7.18 58,388 7 18 440 0.7
6 Myosin 3 NP001078847 5.62 224,755 9 5 141 0.7
7 Tropomyosin, beta chain NP033442 4.66 32,933 3 14 126 0.6
8 Heat shock protein Hsp27 AAA18335 6.45 22,945 2 15 55 0.5
Nitrocellulose sheets were washed and then incubated for
1 hour with secondary peroxidase-conjugated antibodies,
diluted in blocking solution [55]. Immunodecorated bands
were visualized using chemiluminescence substrate (Roche
Diagnostics, Mannheim, Germany). Densitometric scanning
of immunoblots was performed using ImageJ (NIH, USA)
software.
3. Results
3.1. Proteomic Profiling of Tibialis Anterior Muscle. Prior to
the proteomic analysis of differently aged dystrophic tibialis
anterior muscle preparations, the protein complement from
extracts of normalmuscle samples was gel electrophoretically
separated and key proteins identified by mass spectrometry.
This procedure established a select number of reliable
landmark protein spots of a typical proteomic muscle
map for control purposes. Figure 1 shows a representative
fluorescent RuBPs-labelled gel with the electrophoretically
separated protein spot pattern of normal mouse tibialis
anterior muscle. Major 2D protein spots were treated by
in-gel digestion and the most abundant constituent of this
area of the gel identified by mass spectrometry. Table 1
lists the names of identified muscle marker proteins, their
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Figure 1: Two-dimensional gel electrophoretic analysis of normal
mouse tibialis anterior muscle. Shown is a fluorescent RuBPs-
stained gel of total extracts from 8 weeks old tibialis anterior muscle.
Major protein spots are marked by circles and are numbered 1
to 22. See Table 1 for the mass spectrometric identification of 2D
landmark proteins that do not change during aging of the mdx
animal model of Duchenne muscular dystrophy. The pH values of
the first dimension gel system and molecular mass standards of the
second dimension are indicated on the top and on the left of the
panels, respectively.
international accession number, pI-values, their relative
molecular masses, number of matched peptide sequences,
percentage sequence coverage, and Mascot scores. Identified
proteins ranged in molecular mass from 17.1 kDa (spot 22,
myoglobin) to 70.7 kDa (spot 2, unknown protein), and
covered a pI-range from pI 4.6 (spot 20, myosin light chain
MLC3) to pI 8.7 (spot 15, fast troponin subunit TnI). Spots
1 to 22 represent major muscle-associated protein species
with apparent molecular mass to isoelectric point ratios
of 57 kDa/pI 5.2, 71 kDa/pI 5.8, 59 kDa/pI 6.7, 47 kDa/pI 6.7,
43 kDa/pI 6.6, 40 kDa/pI 5.8, 33 kDa/pI 4.7, 33 kDa/pI 4.7,
37 kDa/pI 6.2, 40 kDa/pI 8.3, 36 kDa/pI 8.4, 30 kDa/pI 6.9,
23 kDa/pI 5.6, 23 kDa/pI 5.6, 22 kDa/pI 8.7, 23 kDa/pI 5.7,
21 kDa/pI 5.0, 19 kDa/pI 4.8, 19 kDa/pI 4.8, 19 kDa/pI 4.6,
12 kDa/pI 5.0, and 17 kDa/pI 7.1, respectively (Figure 1).
Electrospray ionization mass spectrometry identified these
marker proteins as isoforms of mitochondrial ATP synthase,
pyruvate kinase, enolase, creatine kinase, actin, tropomyosin,
malate dehydrogenase, aldolase, glyceraldehyde-3-phosphate
dehydrogenase, carbonic anhydrase, triosephosphate iso-
merase, troponin, adenylate kinase, parvalbumin, myo-
globin, and various myosin light chains (Table 1).
3.2. Proteomic Analysis of Dystrophic Tibialis Anterior Mus-
cle during Aging. Following the optimization and initial
mass spectrometric identification of muscle marker proteins
in normal mouse tibialis anterior muscle, fluorescence
high-resolution two-dimensional gel electrophoresis was
employed to detect potential differences in aging-related
protein expression patterns in mdx tibialis anterior muscle.
Figure 2 summarizes analytical gels with 4 biological repeats
of 8 weeks, 12 months, and 22 months old total mdx
muscle extracts. Panels TA MDX 1 to 4, TA MDX 5 to
8 and TA MDX 9 to 12 represent 8 weeks, 12 months,
and 22 months old muscle preparations, respectively. Since
the overall 2D spot patterns of normal versus dystrophic
tibialis anterior muscle were relatively comparable, a detailed
denitometric analysis was carried out in order to evaluate
potential differences in individual protein species. Den-
sitometric scanning was performed with a Typhoon Trio
variable imager and Progenesis 2D analysis software was used
to establish differential expression patterns during muscle
aging. The detailed proteomic survey of dystrophic tibialis
anterior revealed distinct age-related changes in 8 muscle
protein species between 8 weeks and 22months old total mdx
muscle preparations.
3.3. Mass Spectrometric Identification of Protein Alterations
in Aged mdx Tibialis Anterior Muscle. A representative
fluorescent 2D master gel of mdx tibialis anterior muscle
is shown in Figure 3. As compared to a recent study on
senescent mdx diaphragmmuscle, which showed drastic age-
dependent changes in 11 proteins in this severely necrotic
tissue [43], the more mildly affected mdx tibialis anterior
muscle showed less pronounced proteome-wide changes
during the aging process. This finding agrees with the
differing pathology ofmdx legmuscle versusmdx diaphragm
muscle. Skeletal muscle proteins that exhibited significant
alterations in expression levels are marked by circles and
are numbered 1 to 8 in the 2D gel representing the urea-
soluble proteome from mdx tibialis anterior muscle. The
mass spectrometric identification of these altered protein
species is listed in Table 2. Besides listing the names of
identified proteins, their accession number, pI-values, their
relative molecular masses, the number of matched peptide
sequences, percentage sequence coverage, andMS/MS scores,
this table also shows the fold change of individual proteins
affected in dystrophin-deficient mdx tibialis anterior muscle
during aging. Proteins species with a changed concentration
in mdx tibialis anterior muscle ranged in molecular mass
from 23 kDa (heat shock protein Hsp27) to 224 kDa (myosin
3) and covered a pI-range from pI 4.7 (tropomyosin) to
pI 8.5 (electron transferring flavoprotein). An increased
abundance was shown for the CA3 isoform of carbonic
anhydrase (spots 1 and 4), the glycolytic enzyme aldolase
(spot 2), and electron transferring flavoprotein (spot 3). The
key cytosolic enzyme pyruvate kinase (spot 5), myosin 3
(spot 6), tropomyosin (spot 7), and the molecular chaperone
Hsp27 (spot 8) were found to be decreased in mdx tissue.
3.4. Immunoblot Analysis of Novel Proteomic Markers of Mus-
cular Dystrophy. Following the mass spectrometric estab-
lishment of age-related changes in the urea-soluble mdx
tibialis anterior muscle proteome, immunoblotting was used
to investigate the concentration of the two most extensively
changed new markers CA3 and Hsp27 in normal versus
dystrophic preparations. Antibodies to the dystrophin-
associated glycoprotein β-dystroglycan (β-DG), which forms
the main trans-sarcolemmal linker between the extracellular
matrix and the cortical actin cytoskeleton in the fibre
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MDX tibialis anterior
Figure 2: Two-dimensional gel electrophoretic analysis of aging mdx tibialis anterior muscle. Shown are RuBPs-stained gels of total extracts
from 8 weeks (TA MDX 1 to 4), 12 months (TA MDX 5 to 8), and 22 months (TA MDX 9 to 12) old tibialis anterior muscle. Fluorescent
images are shown for the pH 3–10 range.
periphery, were employed to verify the dystrophic status of
mdx tissue samples during aging. Figure 4(a) illustrates the
drastic reduction of β-DG in both 8 weeks and 22 months
old mdx tibialis anterior muscle, which is characteristic of
dystrophinopathy. Equal loading of lanes was ensured by
silver staining of gel electrophoretically separated protein
preparations (not shown). Immunoblotting of young versus
old muscle samples with antibodies to the CA3 isoform of
carbonic anhydrase (Figure 4(b)) and the molecular chap-
erone Hsp27 (Figure 4(c)) showed an increased abundance
of the metabolic enzyme and a decreased concentration of
the small heat shock protein in dystrophin-deficient muscle.
Thus, both the fibre type-specific protein CA3 and the stress
protein Hsp27 represent suitable candidate biomarkers of the
dystrophic phenotype.
4. Discussion
Duchenne muscular dystrophy is one of the most crippling
neuromuscular disorders of childhood [58], therefore war-
ranting detailed large-scale studies into the establishment
of comprehensive biomarker signatures of dystrophinopathy
[30, 31]. In dystrophinopathy, the almost complete absence
of the Dp427 isoform of the membrane cytoskeletal protein
dystrophin causes a drastic reduction of a large number
of surface glycoproteins that in turn triggers a loss of
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Figure 3: Fluorescence gel electrophoretic analysis of aged mdx
tibialis anterior muscle. Shown is a representative RuBPs-labelled
master gel of crude tissue extracts frommdx tibialis anterior muscle.
Protein spots with an age-related change in expression levels are
marked by circles and are numbered 1 to 8. See Table 2 for the
mass spectrometric identification of individual muscle-associated
proteins. The pH values of the first dimension gel system and
molecular mass standards of the second dimension are indicated on
the top and on the left of the panels, respectively.
sarcolemmal integrity. The mdx mouse is a widely used
model system for the evaluation of novel treatment options
to counter-act the symptoms of X-linkedmuscular dystrophy
[59] and basic biomedical research promises to provide the
basis of evidence for the development of novel treatment
regimes, such as stem cell therapy, myoblast transfer, or
exon skipping therapy [60]. Previous proteomic studies
have established a considerable number of novel biomarkers
of secondary changes in dystrophin-deficient organisms
[30]. Besides the cataloging of generally perturbed protein
expression patterns, individual proteomic surveys of mdx
muscles of differing subtype and age have demonstrated a
drastically altered abundance of adenylate kinase isoform
AK1 [36], the luminal Ca2+-binding protein calsequestrin
of the terminal cisternae [16, 41], the cytosolic Ca2+-
buffering element regucalcin [39], mitochondrial isocitrate
dehydrogenase [38], and the muscle-specific molecular
chaperone cvHsp [40, 41]. A recent aging study of the
severely dystrophic mdx diaphragm has demonstrated a
drastic increase in the extracellular matrix proteins collagen
and dermatopontin, the molecular chaperone αB-crystallin,
and the intermediate filament protein vimentin, suggesting
increased accumulation of connective tissue, an enhanced
cellular stress response and compensatory stabilization of
the weakened membrane cytoskeleton in severely dystrophic
muscle tissue [43].
In the present report, proteomic profiling showed that
during the natural aging of the moderately dystrophic tibialis
anterior muscle a number of key skeletal muscle proteins
NOR MDX NOR MDX
β-DG β-DG
8 weeks 22 months
(a) Marker of dystrophinopathy
CA3
CA3
(b) Increased proteomic marker
1 2 3 4
Hsp27 Hsp27
(c) Decreased proteomic marker
Figure 4: Immunoblot analysis of novel marker proteins in normal
versus mdx tibialis anterior muscle during aging. Shown are repre-
sentative immunoblots with expanded views of antibody-decorated
protein bands. Panels (a, b, c) were labeled with antibodies to
the dystrophin-associated glycoprotein β-dystroglycan (β-DG), the
CA3 isoform of the fibre type-specific enzyme carbonic anhydrase,
and the molecular chaperone Hsp27, respectively. Lanes 1 and
2, and lanes 3 and 4, represent 8 weeks versus 22 months old
normal wild type versus dystrophic mdx tibialis anterior muscle,
respectively. Immuno-decorated protein bands are indicated by
arrowheads.
change in abundance. We have studied aged mdx mus-
cle, because dystrophic mouse muscle tissue progressively
deteriorates with age and thus more closely resembles the
neuromuscular pathology seen in Duchenne patients [61].
The age-related pathogenesis of mdx muscle is characterized
by a drastic loss of myofibres and concomitant replacement
by connective tissue [62–64], progressive motor weakness
[65], the presence of branched fibres that trigger mechanical
weakening of the muscle periphery [66], a reduced life span
and increased susceptibility to spontaneous rhabdomyosar-
coma [67], a decline in regenerative potential and alterations
in the crucial mTOR signaling pathway [68], and impaired
functional and structural recovery after injury [54]. Hence,
senescent mdx muscle represents a suitable dystrophic phe-
notype for determining potential global changes in the pro-
tein complement during aging. This report has summarized
the findings of a comparative proteomic analysis of mildly
affected mdx tibialis anterior muscle from 8 weeks versus
22 months old mice. The identification of aldolase, pyruvate
kinase, carbonic anhydrase, tropomyosin, myosin, electron
transferring flavoprotein and small heat shock protein Hsp27
as new indicators of progressive muscular dystrophy might
8 Journal of Biomedicine and Biotechnology
be useful for the establishment of a more comprehensive
biomarker signature of dystrophinopathy.
The protein with the highest age-related increase was
identified as carbonic anhydrase isoform CA3 [69]. In gen-
eral, carbonic anhydrases catalyze the reversible hydration
of CO2 and are widely distributed throughout the body
[70]. Skeletal muscles express several isoforms of this crucial
metabolic enzyme in a fibre-type-specific manner. The
predominant CA3 isoform is mostly present in the cytosolic
fraction of type I and IIa fibers [69]. Interestingly, metabolic
adaptations, altered neuromuscular activity patterns, stretch-
induced hypertrophy, and disuse atrophy greatly influence
the expression of muscle carbonic anhydrases [71–73].
The higher concentration of the CA3 isoform of carbonic
anhydrase in aged mdx muscle, as shown here by mass
spectrometry-based proteomics, could be an indication of
an increased demand for efficient CO2 removal during mdx
fibre aging. On the other hand, since the CA3 isoform is
predominantly located in slower-twitching fibre populations,
its altered density could also be due to age-related fibre-type
shifting in the mdx tibialis anterior muscle. This would agree
with the findings of a recent proteomic survey of middle
aged versus aged vastus lateralis muscle, which revealed
increased levels of CA3 in senescent human skeletal muscle
[74].
The greatest reduction in a muscle-associated protein
during aging of the mdx tibialis anterior was shown to be
the small heat shock protein Hsp27. This indicates a poten-
tially blunted cellular stress response in dystrophic tibialis
anterior fibres and demonstrates that marked differences
exist with respect to expression levels of small heat shock
proteins in moderately affected hind limb muscles versus
severely dystrophic diaphragm muscle in the mdx model
of dystrophinopathy [40, 41]. While changes in elements of
the contractile apparatus suggest downstream effects of dys-
trophin deficiency onmyosin and tropomyosin organization,
altered expression levels in electron transferring flavoprotein
and glycolytic enzymes indicate perturbed mdx muscle
metabolism. The beta-polypeptide chain of the electron
transferring flavoprotein is involved in mitochondrial fatty
acid and amino acid catabolism and mediates the shuttling
of electrons between flavoprotein dehydrogenases [75]. The
enzymes aldolase and pyruvate kinase catalyze the reversible
break-down of fructose-1,6-biphosphate into dihydroxyace-
tone phosphate and glyceraldehyde-3-phosphate and the
critical oxidoreduction-phosphorylation step that converts
ADP and phosphoenolpyruvate to ATP and pyruvate, respec-
tively [76]. Alterations in glycolytic enzymes and mito-
chondrial proteins in mdx tibialis anterior muscle indicate
altered flux rates through key metabolic pathway. With
respect to the glycolytic pathway, the activity of four muscle
proteins is central to its regulation on the enzymatic level,
i.e. the metabolic flux through hexokinase, phosphofructok-
inase, glycogen phosphorylase, and pyruvate kinase, whereby
metabolic silencing of muscle glycolysis is probably mediated
by the inactivation of pyruvate kinase [76]. This central
role of pyruvate kinase in muscle metabolism makes its
changed abundance in the mdx tibialis anterior muscle a
crucial finding. Pyruvate kinase was previously shown to
be a suitable biomarker of the general aging process in
skeletal muscle tissues [77, 78]. Interestingly, the change of
metabolic enzymes in agedmdx tibialis anterior muscle, such
as pyruvate kinase and aldolase, agrees with the proteomic
analysis of golden retriever muscular dystrophy. In the grmd
dogmodel of dystrophinopathy, targets of the transcriptional
control factor of energy metabolism PGC-1α, that is, various
glycolytic and oxidative enzymes, were found to be reduced
[44].
In conclusion, the comparative proteomic survey of
dystrophic tibialis anterior muscle from 8 weeks versus 22
months old mdx mice has revealed altered expression levels
in a number of critical proteins during skeletal muscle
aging. However, the degree of concentration changes was less
pronounced in the moderately dystrophic tibialis anterior
muscle as compared to the recently analyzed aged mdx
diaphragm [43]. These differing proteomic findings agree
with the pathophysiological concept that the aged mdx
diaphragm muscle is more severely affected as compared to
moderately necrotic mdx hind limb muscle. In the long-
term, the proteomic identification of new biomarkers of
dystrophinopathy might be useful for the establishment
of a comprehensive and muscle subtype-specific signature
of Duchenne muscular dystrophy. This would be use-
ful for improving diagnostic procedures, monitor disease
progression, identify novel therapeutic targets and aid in
the evaluation of novel treatments, such as exon-skipping
therapy or stem cell therapy.
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